+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Papillomavirus Vaccine Market by Vaccine Type, Technology Platform, Age Group, Gender, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Human Papillomavirus Vaccine Market by Vaccine Type, Technology Platform, Age Group, Gender, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Human Papillomavirus Vaccine Market by Vaccine Type, Technology Platform, Age Group, Gender, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4858029
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Human Papillomavirus Vaccine Market is projected to reach USD 5.27 Billion in 2026. It is expected to continue growing at a CAGR of 7.26%, reaching USD 8.05 Billion by 2032.

Human papillomavirus vaccine remains one of the most evidence-supported interventions in cancer prevention, targeting HPV types linked to cervical cancer, anal cancer, oropharyngeal cancer, vulvar and vaginal cancers, penile cancer, and genital warts. The World Health Organization identifies HPV as the cause of nearly all cervical cancers, and HPV types 16 and 18 account for most HPV-related cervical cancer cases globally.

Market momentum is shaped by national immunization programs, gender-neutral vaccination policies, school-based delivery, and the transition toward broader-valent vaccines, including 9-valent HPV vaccination where approved and recommended. Demand is also supported by the WHO cervical cancer elimination strategy, which calls for 90% of girls to be fully vaccinated against HPV by age 15 by 2030, alongside expanded screening and treatment targets.

Transformative Shifts in the HPV Vaccine Landscape

The HPV vaccine landscape is shifting from a primarily female adolescent cervical cancer prevention model to a broader cancer prevention platform that includes boys, young adults, catch-up cohorts, and high-risk populations. Public health agencies in multiple high-income countries now recommend routine vaccination for both girls and boys, improving herd protection and supporting prevention of HPV-related cancers across genders.

Another major shift is the growing acceptance of simplified dosing schedules. WHO’s Strategic Advisory Group of Experts has supported single-dose HPV vaccination as an alternative schedule for selected age groups, a change that can reduce delivery costs, improve completion rates, and expand access in low- and middle-income countries where supply, financing, and school-based infrastructure remain constraints.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing the HPV vaccine ecosystem through demand planning, supply allocation, pharmacovigilance signal detection, and precision outreach. AI-enabled analytics can help immunization programs identify under-vaccinated communities, model missed-dose risk, and optimize appointment reminders, which is especially important because HPV vaccine coverage often varies by geography, income, and access to primary care.

AI also strengthens the evidence chain around cervical cancer elimination by connecting vaccination data with screening registries, electronic health records, and population health dashboards. While AI does not replace clinical guidance, it can accelerate real-world evidence generation, improve cold-chain visibility, support adverse event monitoring, and guide targeted communication strategies that address misinformation and vaccine hesitancy.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific represents a high-impact region because it includes large adolescent populations, expanding public immunization programs, and countries with significant cervical cancer burden. China, India, Japan, Australia, and South Korea are at different stages of HPV vaccine adoption, with Australia recognized for strong school-based vaccination and cervical screening integration, while India’s locally developed HPV vaccine capability is improving affordability and supply resilience for public health programs.

North America shows mature demand driven by established recommendations, reimbursement pathways, and cancer prevention awareness. The United States and Canada benefit from strong regulatory and advisory systems, routine adolescent immunization guidance, and provider-led vaccine delivery. Latin America has meaningful opportunities in Brazil, Mexico, and neighboring countries that use public procurement, school-based delivery, and national vaccination campaigns to improve coverage. Europe benefits from national immunization schedules and increasing gender-neutral recommendations, supported by cancer prevention priorities across many countries. The Middle East is advancing through prevention-focused health policy, especially in higher-income systems, while Africa remains a priority for cervical cancer elimination because many countries face high disease burden and rely on financing support, delivery partnerships, and health system strengthening to improve HPV vaccine access.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN presents a diverse HPV vaccine opportunity, with Singapore, Malaysia, Thailand, Indonesia, the Philippines, Vietnam, and other member states differing in funding models, school health infrastructure, procurement capacity, and public awareness. Regional progress is strongly linked to affordability, national immunization financing, school-based delivery, and integration with adolescent health programs.

The GCC is characterized by higher healthcare spending capacity and growing prevention-focused policy agendas, making gender-neutral vaccination, school health initiatives, and organized cancer prevention campaigns strategically relevant. The European Union benefits from coordinated cancer prevention priorities and national immunization schedules, although coverage still varies by member state because implementation, reimbursement, and public confidence differ. BRICS countries are central to global HPV vaccination expansion because Brazil, Russia, India, China, and South Africa combine large populations with public-sector procurement potential and evolving domestic vaccine policy. G7 countries generally demonstrate strong regulatory capacity, surveillance infrastructure, payer support, and real-world evidence systems, while NATO members, many of which overlap with high-income European and North American immunization systems, benefit from established public health infrastructure that supports vaccine safety monitoring, adolescent immunization delivery, and higher-valent vaccine adoption where recommended.

Key Country Insights Across Major HPV Vaccine Markets

The United States remains a leading HPV vaccine market due to ACIP recommendations, broad pediatric provider networks, and regulatory approval of the 9-valent vaccine for eligible individuals. Canada, the United Kingdom, Germany, France, Italy, Spain, Japan, Australia, and South Korea rely on national or regional immunization programs, with performance influenced by school-based administration, reimbursement, reminder systems, and public confidence. Australia remains a benchmark for integrated HPV vaccination, cervical screening, and cervical cancer elimination planning, while Japan’s trajectory reflects renewed policy focus following earlier periods of public confidence challenges.

Mexico and Brazil are important Latin American markets where public-sector procurement, national vaccination campaigns, and school or clinic-based delivery shape uptake. China and India represent two of the largest long-term access priorities, supported by large adolescent cohorts, rising cancer prevention awareness, inclusion of HPV vaccination in expanding public health discussions, and growing domestic manufacturing capability. Russia’s market is influenced by regional program adoption and access variability, while Germany, France, Italy, and Spain continue to align HPV vaccination with broader cancer prevention strategies. The United Kingdom maintains a well-established school-based program, Canada emphasizes provincial and territorial delivery, South Korea benefits from organized national immunization policy, and Japan, Australia, and China remain central to Asia-Pacific HPV vaccine dynamics.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize reliable supply, affordable pricing, and partnerships with governments, global health organizations, school systems, and primary care networks. Organizations that support national immunization goals with evidence-based education, simplified logistics, transparent safety communication, and robust pharmacovigilance can improve trust while expanding equitable access.

Strategic investment should focus on gender-neutral policy engagement, real-world effectiveness studies, digital reminder systems, and culturally appropriate communication that addresses vaccine hesitancy. Manufacturers and distributors should also prepare for expanding demand in underserved markets by strengthening cold-chain networks, local partnerships, public procurement readiness, and data systems that help health authorities monitor coverage and completion.

Research Methodology

Research methodology is grounded in secondary research from recognized public health and regulatory sources, including WHO guidance, national immunization advisory recommendations, public cancer prevention data, vaccine policy updates, regulatory information, and peer-reviewed evidence on HPV vaccination effectiveness. Market interpretation emphasizes verified trends rather than speculative sizing.

The methodology integrates policy analysis, regional adoption patterns, immunization program structures, and technology impact assessment. Insights are triangulated across public health objectives, regulatory approvals, procurement dynamics, vaccine safety evidence, and documented shifts in vaccine schedules, school-based delivery, gender-neutral recommendations, and coverage strategies.

Conclusion

The HPV vaccine market is moving from incremental immunization adoption toward a global cancer elimination agenda. Proven clinical value, evolving dosing flexibility, and broader gender-neutral vaccination policies position HPV vaccines as a core preventive health priority across adolescent health, women’s health, and cancer prevention programs.

Future progress will depend on equitable access, resilient supply, public confidence, and data-driven program execution. Organizations that combine scientific credibility with scalable delivery models will be best positioned to support cervical cancer elimination and broader prevention of HPV-related cancers.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Human Papillomavirus Vaccine Market, by Vaccine Type
7.1. Nonavalent
7.2. Bivalent
7.3. Quadrivalent
8. Human Papillomavirus Vaccine Market, by Technology Platform
8.1. Recombinant Protein-Based Vaccines
8.2. Yeast Expression System-Based Vaccines
8.3. Insect Cell-Based Recombinant Vaccines
8.4. Novel Platforms
9. Human Papillomavirus Vaccine Market, by Age Group
9.1. 15-26 Years
9.2. 27 Years And Above
9.3. 9-14 Years
10. Human Papillomavirus Vaccine Market, by Gender
10.1. Female
10.2. Male
11. Human Papillomavirus Vaccine Market, by End User
11.1. Clinics
11.2. Hospitals
11.3. Public Health Centers
12. Human Papillomavirus Vaccine Market, by Distribution Channel
12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies
13. Asia-Pacific Human Papillomavirus Vaccine Market
14. North America Human Papillomavirus Vaccine Market
15. Latin America Human Papillomavirus Vaccine Market
16. Europe Human Papillomavirus Vaccine Market
17. Middle East Human Papillomavirus Vaccine Market
18. Africa Human Papillomavirus Vaccine Market
19. ASEAN Human Papillomavirus Vaccine Market
20. GCC Human Papillomavirus Vaccine Market
21. European Union Human Papillomavirus Vaccine Market
22. BRICS Human Papillomavirus Vaccine Market
23. G7 Human Papillomavirus Vaccine Market
24. NATO Human Papillomavirus Vaccine Market
25. United States Human Papillomavirus Vaccine Market
26. China Human Papillomavirus Vaccine Market
27. India Human Papillomavirus Vaccine Market
28. United Kingdom Human Papillomavirus Vaccine Market
29. Canada Human Papillomavirus Vaccine Market
30. Russia Human Papillomavirus Vaccine Market
31. Germany Human Papillomavirus Vaccine Market
32. France Human Papillomavirus Vaccine Market
33. Italy Human Papillomavirus Vaccine Market
34. Australia Human Papillomavirus Vaccine Market
35. Japan Human Papillomavirus Vaccine Market
36. Brazil Human Papillomavirus Vaccine Market
37. Mexico Human Papillomavirus Vaccine Market
38. South Korea Human Papillomavirus Vaccine Market
39. Spain Human Papillomavirus Vaccine Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. AstraZeneca plc
41.2. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
41.3. Bharat Biotech International Limited
41.4. Biological E. Limited
41.5. BioNTech SE
41.6. Chengdu Institute of Biological Products Co., Ltd.
41.7. China National Biotec Group Company Limited
41.8. Daiichi Sankyo Company, Limited
41.9. Fujifilm Holdings Corporation
41.10. GlaxoSmithKline plc
41.11. Hilleman Laboratories
41.12. IDT Biologika GmbH
41.13. Inovio Pharmaceuticals, Inc.
41.14. Jiangsu Recbio Technology Co., Ltd.
41.15. Johnson & Johnson
41.16. LG Chem Ltd.
41.17. Medigen Vaccine Biologics Corporation
41.18. Merck & Co., Inc.
41.19. Mitsubishi Tanabe Pharma Corporation
41.20. Moderna, Inc.
41.21. Novavax, Inc.
41.22. Panacea Biotec Limited
41.23. Pfizer Inc.
41.24. Sanofi S.A.
41.25. Serum Institute of India Pvt. Ltd.
41.26. Shanghai Zerun Biotechnology Co., Ltd.
41.27. Shenzhen Kangtai Biological Products Co., Ltd.
41.28. Shionogi & Co., Ltd.
41.29. Sinopharm Group Co., Ltd.
41.30. SK bioscience Co., Ltd.
41.31. Takeda Pharmaceutical Company Limited
41.32. Walvax Biotechnology Co., Ltd.
41.33. Xiamen Innovax Biotech Co., Ltd.
List of Figures
FIGURE 1. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 25. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NONAVALENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NONAVALENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NONAVALENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BIVALENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BIVALENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BIVALENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL QUADRIVALENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL QUADRIVALENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL QUADRIVALENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL RECOMBINANT PROTEIN-BASED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL RECOMBINANT PROTEIN-BASED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL RECOMBINANT PROTEIN-BASED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL YEAST EXPRESSION SYSTEM-BASED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL YEAST EXPRESSION SYSTEM-BASED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL YEAST EXPRESSION SYSTEM-BASED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL INSECT CELL-BASED RECOMBINANT VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL INSECT CELL-BASED RECOMBINANT VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL INSECT CELL-BASED RECOMBINANT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NOVEL PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NOVEL PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NOVEL PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL 15-26 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL 15-26 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL 15-26 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL 27 YEARS AND ABOVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL 27 YEARS AND ABOVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL 27 YEARS AND ABOVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL 9-14 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL 9-14 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL 9-14 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL FEMALE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL FEMALE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL FEMALE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MALE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MALE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MALE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 91. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 92. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 93. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 94. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 105. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 106. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 107. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 108. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 112. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 113. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 114. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 115. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 117. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 119. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 120. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 121. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 122. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 133. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 134. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 135. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 136. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 140. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 141. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 142. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 143. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 147. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 148. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 149. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 150. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 153. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 154. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 156. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 160. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 161. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 162. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 163. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 164. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 167. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 168. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 169. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 170. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 171. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 174. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 175. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 176. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 177. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 178. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 181. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 182. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 183. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 184. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 185. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 187. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 189. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 190. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 191. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 192. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 195. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 196. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 197. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 198. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 199. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 201. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 202. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 203. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 204. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 205. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 206. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 210. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 211. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 212. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 213. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 214. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 215. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 216. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 217. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 218. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 219. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 220. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 222. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 223. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 224. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 225. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 226. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 227. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 230. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 231. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 232. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 233. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 234. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 235. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 236. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 237. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 238. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 239. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 240. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 241. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 243. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 244. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 245. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 246. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 247. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 248. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 249. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 250. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 251. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 252. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 253. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 254. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 255. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 256. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Human Papillomavirus Vaccine market report include:
  • AstraZeneca plc
  • Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
  • Bharat Biotech International Limited
  • Biological E. Limited
  • BioNTech SE
  • Chengdu Institute of Biological Products Co., Ltd.
  • China National Biotec Group Company Limited
  • Daiichi Sankyo Company, Limited
  • Fujifilm Holdings Corporation
  • GlaxoSmithKline plc
  • Hilleman Laboratories
  • IDT Biologika GmbH
  • Inovio Pharmaceuticals, Inc.
  • Jiangsu Recbio Technology Co., Ltd.
  • Johnson & Johnson
  • LG Chem Ltd.
  • Medigen Vaccine Biologics Corporation
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Moderna, Inc.
  • Novavax, Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Shanghai Zerun Biotechnology Co., Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Shionogi & Co., Ltd.
  • Sinopharm Group Co., Ltd.
  • SK bioscience Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Walvax Biotechnology Co., Ltd.
  • Xiamen Innovax Biotech Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages190
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.27 Billion
Forecasted Market Value ( USD ) by 2032 $ 8.05 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned34

Related Topics

Related Reports

Human Papillomavirus Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Human Papillomavirus Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 77 Pages
  • Global
From
Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccines - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

Human Papillomavirus (HPV) Vaccines - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
Human Papillomavirus (Hpv) Vaccine Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Human Papillomavirus (Hpv) Vaccine Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccines Market - Global Strategic Business Report - Product Image

Human Papillomavirus (HPV) Vaccines Market - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From

About the HPV Vaccine Market

The HPV Vaccine is a type of cancer vaccine used to prevent infection from the human papillomavirus (HPV). HPV is a virus that can cause cervical cancer, as well as other types of cancer. The HPV Vaccine is typically administered to adolescents and young adults, and is recommended by the World Health Organization (WHO) as part of routine immunization programs. The vaccine is available in both a bivalent and quadrivalent form, and is designed to protect against the two most common types of HPV that cause cervical cancer. The HPV Vaccine market is a rapidly growing segment of the cancer vaccine market. It is estimated that the global HPV Vaccine market will reach $4.5 billion by 2027, driven by increasing awareness of the virus and its associated health risks, as well as the availability of the vaccine in many countries. Some of the major companies in the HPV Vaccine market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and CSL. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.